- Contact Us
- Locations & Directions
- Medical Staff Directory
- Careers
- Giving
- International Patients




Find a Clinical Trial by Phase
- Anus
- Brain and Nervous System
- Breast
- Cervix
- Colon
- Disease-free
- Endometrium
- Esophagus
- Eye and Orbit
- Head & Neck
- Hodgkin's Lymphoma
- Kaposi's Sarcoma
- Kaposi's sarcoma
- Kidney
- Leukemia
- Liver
- Lung
- Melanoma
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Ovary
- Pancreas
- Prostate
- Rectum
- Sarcoma
- Small Intestine
- Stomach
- Thyroid
- Urinary Bladder
- Uterus
New studies open frequently, please check back for updates
- Anus
- Brain and Nervous System
- Eye and Orbit
- Hodgkin's Lymphoma
- Kidney
- Leukemia
- Liver
- Lung
- Melanoma
- Myeloid leukemia
- Non-Hodgkin's Lymphoma
- Ovary
- Pancreas
- Prostate
- Rectum
- Sarcoma
- Small Intestine
- Stomach
- Thyroid
- Urinary Bladder
New studies open frequently, please check back for updates
- Ahdoot, Michael
- Al-Louzi, Omar
- Amersi, Farin
- Anand, Neel
- Arditi, Moshe
- Asher, Arash
- Ayodele, Maranatha
- Ayoub, Walid
- Azam, Salman
- Baca, Nicole
- Bae, Hyun
- Bairey-Merz, Noel
- Balmanoukian, Ani
- Basho, Reva
- Ben-Shlomo, Anat
- Burch, Miguel
- Burford, Matthew
- Burwick, Richard
- Chaux, George
- Chen, Peng-Sheng
- Chen, Peter
- Chikwe, Joanna
- Chiu, Vi K.
- Cooper, Odelia
- D'Agnolo, Alessandro
- Danovitch, Itai
- Darrah, Justin
- Daskivich, Timothy
- Diaz, Frank
- Eboli, Paula
- Ehdaie, Ashkan
- Esmailian, Fardad
- Faries, Mark
- Figlin, Robert
- Figueiredo, Jane
- Fleshner, Phillip
- Franco, Mercedes
- Freedland, Stephen
- Friedman, Oren
- Gaddam, Srinivas
- Gangi, Alexandra
- Garcia, Maurice
- Gayther, Simon
- Giuliano, Armando
- Gong, Jun
- Goodarzi, Mark
- Gresham, Gillian
- Gupta, Amit
- Gupta, Navyash
- Gutierrez, Rodolfo
- Hage, Antoine
- Hamid, Omid
- Hendifar, Andrew
- Hitchins, Megan
- Ho, Allen
- Hu, Jethro
- Huang, Edmund
- Irwin, Scott
- Jeon, Christie
- Jordan, Stanley
- Kamil, Elaine
- Kamrava, Mitchell
- Karumanchi, Subbian
- Khandwalla, Raj
- Kim, Hyung
- Kransdorf, Evan
- Kulber, David
- Labadzhyan, Artak
- Lawrenson, Kate
- Lewis, Richard
- Li, Andrew
- Liu, Quin
- Lo, Simon
- Majlessipour, Fataneh
- Makkar, Rajendra
- Markush, Dor
- McKinnell, James
- Mehmi, Inderjit
- Melmed, Gil
- Merchant, Akil
- Merin, Noah
- Mita, Alain
- Mita, Monica
- Moon, Charles
- Natale, Ronald
- Noureddin, Mazen
- Osipov, Arsen
- Padda, Sukhmani
- Pandol, Stephen
- Paquette, Ronald
- Paski, Shirley
- Patel, Jignesh
- Patil, Chirag
- Posadas, Edwin
- Rader, Florian
- Reckamp, Karen
- Reinisch, John
- Rimel, Bobbie Jo
- Rokhsar, Sepehr
- Rosenbloom, Barry
- Rosser, Charles
- Rudnick, Jeremy
- Sandler, Howard
- Shehata, Michael
- Shiao, Stephen
- Shirazipour, Celina
- Sicotte, Nancy
- Siegel, Robert
- Skaggs, David
- Sleight Warner, Alexandra (Alix)
- Song, Shlee
- Spiegel, Brennan
- Stone, Michael
- Sundaram, Vinay
- Syal, Gaurav
- TEST, STAFF2
- TEST, STAFF3
- Tagliati, Michele
- Tajbakhsh, Jian
- Tan, Echo
- Tapson, Victor
- Thompson, Patricia
- Toossi, Shahed
- Torbati, Sam
- Vescio, Robert
- Vrahas, Mark
- Wachsman, Ashley
- Wentzel, Kristopher
- Wu, Arthur
- Wyman, R. Michael
- Yang, Ju Dong
- Zabner, Rachel
- Zaghiyan, Karen
- Zahn, Evan
- Zaman, Tanzira
- Zumsteg, Zachary
The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.
- 177Lu-PNT2002
- 5-fluorouracil
- ALKS 4230
- ALX148
- AMG 510
- AMG 650
- ASP9801
- ASTX295
- AZD-2281
- Abiraterone
- Abiraterone Acetate
- Abraxane
- Adriamycin
- Adrucil
- Alimta
- Ancef
- Apalutamide
- BNT411
- BPM31510
- Blinatumomab
- Brentuximab vedotin
- CC-486
- CPT-11
- Cabozatinib
- Camptosar
- Capecitabine
- Carboplatin
- Cefazolin
- Cetuximab
- Cubicin
- Cyclophosphamide
- Cytarabine
- Cytosar
- Cytoxan
- DAY101
- DEFINITY
- DKN-01
- DPX-Survivac
- DTIC
- Dacarbazine
- Daptomycin
- Decadron
- Degarelix
- Dexamethasone
- Docetaxel
- Doxorubicin
- ENB-003
- Eloxatin
- Erbitux
- Etoposide
- FHD-286
- Filgrastim
- Fludara
- Fludarabine
- GSK6097608
- Gefitinib
- Gemzar
- Goserelin
- HMBD-002
- Hycamtin
- IBI322
- IMC-C103C
- INCA00186
- INCB106385
- ITIL-168
- I^131-Metaiodobenzylguanidine (I^131-MIBG)
- Interleukin 2
- Iressa
- JNJ-61186372
- JNJ-73841937
- JTX-4014
- JTX-8064
- Ketorolac
- L-glutamine
- Lisinopril
- Lomustine
- Lonsurf
- Lumason
- Lupron
- MDX-101
- MEDI1191
- MK-7684
- Mercaptopurine
- Methotrexate
- Mutamycin
- NC318
- NGM831
- NT219
- Nafcillin
- NanoPac
- Necitumumab
- Neulasta
- Neupogen
- Nivolumab
- Olaparib
- Oncaspar
- Onivyde
- Oxaliplatin
- Paclitaxel
- Paclitaxel Protein-Bound
- Panitumumab
- Paraplatin
- Pegaspargase
- Pegfilgrastim
- Pemetrexed
- Platinol
- Prednisone
- Purinethol
- REGN6569
- RO7247669
- RTX-240
- Regorafenib
- Rituxan
- Rituximab
- SEA-CD40
- SGN-STNV
- Savolitinib
- Selumetinib
- TBX-3400
- TH1902
- Tabloid
- Taxol
- Taxotere
- Temodar
- Temozolomide
- Thioguanine
- Tislelizumab
- Tocilizumab
- Topotecan
- Toradol
- Vancomycin
- Vancomycin Enema/Nss Irrigat
- Vectibix
- Vepesid
- Vinblastine
- Vincristine
- Vitamin K
- XL-184
- XL092
- XMT-1536
- Xeloda
- Yervoy
- Zestril
- Zoladex
- Zytiga
- alectinib
- amivantamab
- atezolizumab
- avelumab
- belzutifan
- buserelin
- cemiplimab
- cisplatin
- dalbavancin
- dostarlimab
- durvalumab
- duvelisib
- enzalutamide
- etigilimab
- gemcitabine
- histrelin
- inavolisib
- ipilimumab
- irinotecan
- lazertinib
- lenvatinib
- leucovorin
- mFOLFIRINOX
- mitomycin
- osimertinib
- pembrolizumab
- retifanlimab
- selpercatinib
- sotorasib
- tiragolumab
- triptorelin
- Back to Phases
Phase: I
77 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.
Doctor | Protocol No. | Title |
---|---|---|
Ayoub, Walid | TERN201-1007 | A Multi-Center, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Proof of Concept, Adaptive, Phase 1b Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Orally Administered TERN-201 in Patients with Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) |
Balmanoukian, Ani | C-800-01 | A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer (IRB#1612) |
Balmanoukian, Ani | SGN228-001 | A phase 1 study of SGN-CD228A in select advanced solid tumors (IRB#138) |
Balmanoukian, Ani | SGNSTNV-001 | A Phase 1 Study of SGN-STNV in Advanced Solid Tumors (IRB#1148) |
Basho, Reva | TAK-676-1003 | TAK-676-1003: An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non Small-Cell Lung Cancer, Triple-Negative Breast Cancer, or Squamous-Cell Carcinoma of the Head and Neck that Has Progressed on Checkpoint Inhibitors (IRB#1378) |
Chaux, George | STUDY00000883 | Respiratory application of a novel ultraviolet light delivery device for patients infected with COVID-19: A Pilot Study |
Chiu, Vi K. | 831-IO-101 | 831-IO-101: A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors (IRB#1779) |
Darrah, Justin | CRSP-ONC-001 | CRSP-ONC-001: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies (IRB#1154) |
Darrah, Justin | GCT3013-02 | GCT3013-02: A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody® CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma (IRB#1087) |
Fleshner, Phillip | TU100P2T4 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery (ERAS) protocol in Subjects Undergoing Bowel Resection. |
Friedman, Oren | CAP-1002COVID-19-2 | Protocol CAP-1002 in Severe COVID-19 Disease: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF INTRAVENOUS DELIVERY OF CAP-1002 IN PATIENTS WITH SEVERE COVID-19 (INSPIRE) |
Gong, Jun | IIT2020-02-GONG-GLUTAPANC | IIT2020-02-Gong-GlutaPanc: Phase I trial of first-line L-glutamine with gemcitabine and nab-paclitaxel in advanced pancreatic cancer (GlutaPanc) (IRB#1113) |
Gong, Jun | WO42758 | WO42758: A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER (INTRINSIC) (IRB# 1565) |
Gupta, Navyash | SAVVE-STUDY01-21-US | The Hancock Jaffe Surgical Antireflux Venous Valve Endoprosthesis (SAVVE) Study |
Gutierrez, Rodolfo | IMC-C103C-101 | A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer (IRB#56562) |
Gutierrez, Rodolfo | TYR-219-01 | A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced solid tumors and Head and Neck cancer (IRB#907) |
Hamid, Omid | 212214 | 212214: A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors (IRB#688) |
Hamid, Omid | ALKS4230-001 | ALKS4230-001: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors-ARTISTRY-2 (001) (IRB#0539) |
Hamid, Omid | BO43328 | BO43328: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA (MORPHEUS-MELANOMA) (IRB#1699) |
Hamid, Omid | C4401001 | C4401001: A Phase 1 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PF-07257876 in Patients with Advanced or Metastatic Tumors (IRB#1500) |
Hamid, Omid | CIBI322A102 | CIBI322A102 A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumors. (IRB#1021) |
Hamid, Omid | D8510C00001 | D8510C00001: A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors (IRB#57295) |
Hamid, Omid | ENB-003-101-MK3475-951 | ENB-003-101-MK3475-951: A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (IRB#1470) |
Hamid, Omid | IMC-F106C-101 | IMC-F106C-101: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A 02:01-Positive Participants with Advanced PRAME-Positive Cancers (STUDY#513) |
Hamid, Omid | INCA0186-101 | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors (IRB#1544) |
Hamid, Omid | INCAGN2385-201 | INCAGN2385-201: A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti PD-1), INCAGN02385 (Anti LAG-3), and INCAGN02390 (Anti TIM-3) in Participants With Select Advanced Malignancies (IRB#00685) |
Hamid, Omid | LOKON003 | LOKON003: A Phase I/II Trial Investigating LOAd703 in Combination with Atezolizumab in Malignant Melanoma (IRB#525) |
Hamid, Omid | MK-3475-U02-01 | MK-3475-U02-01: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma: Master (KEYNOTE-U02) (IRB#595) |
Hamid, Omid | MPH313-1-02 | MPH313-1-02: A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors (IRB#1277) |
Hamid, Omid | NC318-01 | NC318-01: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors (IRB#54833) |
Hamid, Omid | R6569-ONC-1933 | R6569-ONC-1933: A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR mAb, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES (IRB#920) |
Hamid, Omid | RTX-240-01 | PHASE 1/2 STUDY OF RTX-240 MONOTHERAPY (IRB#596) |
Hamid, Omid | TWT-101 | TWT-101: A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies (IRB#819) |
Hendifar, Andrew | RGX-202-001 | RGX-202-001: A Phase 1 Study of RGX-202-01, a Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (IRB#55176) |
Irwin, Scott | IIT2019-18-IRWIN-KETANX | IIT2019-18-IRWIN-KETANX: A Prospective, Single Center, Double Blind, Randomized, Crossover Feasibility Study of Oral Ketamine versus Placebo for the Treatment of Anxiety in Patients with Pancreatic Cancer (IRB#1632) |
Jordan, Stanley | IIT-JORDAN-2020 | A Phase I/II, Double-Blind, Placebo-Controlled Study: Assessing Safety and Efficacy of Preoperative Renal Allograft Infusions of C1 Inhibitor (Berinert®) (Human) (C1INH) vs. Placebo Administration in Recipients of a Renal Allograft from Deceased High Risk Donors and its impact on Delayed Graft Function (DGF) and Ischemia/Reperfusion Injury (IRI) |
Lewis, Richard | CNS10-NPC-GDNF | Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) Delivered to the Motor Cortex for the Treatment of Amyotrophic Lateral Sclerosis |
Makkar, Rajendra | 2019-06-EVOQUE | Early Feasibility Study of the Edwards EVOQUE Tricuspid Valve Replacement System |
Makkar, Rajendra | ABT-CIP-10354 | Cephea Early Feasibility Study |
Mehmi, Inderjit | 20190131 | 20190131 : A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors (IRB#705) |
Mehmi, Inderjit | DAY101-102 | A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations (IRB#1473) |
Mehmi, Inderjit | FHD-286-C-001 | A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects with Metastatic Uveal Melanoma (IRB#1365) |
Mehmi, Inderjit | SRF617-101 | SRF617: A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors (IRB#811) |
Mehmi, Inderjit | TBX-3400-001 | TBX-3400-001: A Phase 1 Multi-Center Dose-Escalation Study of The Safety, Tolerability and Early Efficacy of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors (IRB#1000) |
Mehmi, Inderjit | TBX-3400-003 | TBX-3400-003: A Phase 1/2 Multi-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Subjects with Solid Malignant Tumors Resistant or Refractory to Standard Therapies (IRB#1675) |
Melmed, Gil | STUDY00000256 | A Multicenter Randomized, Double-Blinded, Placebo-Controlled Study of Posaconazole in Genetically-Defined Patients with Active Crohn's Disease. |
Merin, Noah | IIT2017-05-MERIN-BLINHMCT | IIT2017-05-Merin-BlinHMCT: Blinatumomab plus HLA Mismatched Cellular Therapy (HMCT) for Relapsed Refractory CD19+ ALL (IRB#52176) |
Mita, Alain | 61186372NSC1003 | 61186372NSC1003: An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies (IRB#1175) |
Mita, Alain | ASTX029-01 | ASTX029-01: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors (IRB#54467) |
Mita, Alain | ASTX295-01 | ASTX295-01: Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors (IRB#016) |
Mita, Alain | BNT411-01 | BNT411-01: Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC) (IRB#578) |
Mita, Alain | IIT2021-04-MITA-DZ002 | IIT2021-04-Mita-DZ002: A Phase 1 Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients with Advanced Solid Malignancies or Lymphoma (IRB#01430) |
Mita, Alain | Q702-ONC-P1-US001 | Q702-ONC-P1-US001: A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors (IRB#1380) |
Mita, Monica | C4551001 | C4551001: A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (IRB#1043) |
Mita, Monica | GEN-602-CT-101 | GEN-602-CT-101: A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Given orally on a daily x 21 days followed by 7 Days off schedule in patients with Advanced Solid Tumors or Lymphoma (IRB#56184) |
Mita, Monica | HMBD-002-V4C26-01 | HMBD-002-V4C26-01: A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced Solid Malignancies (IRB#1841) |
Mita, Monica | INCB106385-102 | INCB106385-102: A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors (IRB#1094) |
Mita, Monica | JTX-8064-101 | JTX-8064-101:Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies (IRB#1498) |
Mita, Monica | LNS-101 | LNS-101: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer (IRB#315) |
Mita, Monica | M16-573 | M16-573: A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid tumors (IRB#24) |
Mita, Monica | MINNELIDE101 | MINNELIDE101: A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide Capsules given alone or in combination with Protein-Bound Paclitaxel in patients with Advanced Solid Tumors (IRB#49784) |
Mita, Monica | MT-5111-001 | MT-5111-001: A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (IRB#144) |
Mita, Monica | RGX-104-001 | A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (IRB#46271) |
Mita, Monica | SQZ-PBMC-HPV-101 | SQZ-PBMC-HPV-101: A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (IRB#577) |
Mita, Monica | SY-5609-101 | SY-5609-101: A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors (IRB#1358) |
Mita, Monica | TH1902-CTR-001 | TH1902-CTR-001:A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer, and Pancreatic Cancer (IRB#1343) |
Reckamp, Karen | 73841937NSC1001 | 73841937NSC1001: An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer (IRB#910) |
Reckamp, Karen | BLU-945-1101 | BLU-945-1101: A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer (IRB#1446) |
Reinisch, John | 3DBIO12A2020 | A Multicenter, Single Arm, Prospective, Open-Label, Staged Study of the Safety and Efficacy of the AuriNovo Construct for Auricular Reconstruction in Subjects with Unilateral Microtia |
Rimel, Bobbie Jo | MER-XMT-1536-1 | MER-XMT-1536-1/GOG-3048: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (IRB#919) |
Rudnick, Jeremy | APL-101-01 | APL-101-01: Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumor (IRB#898) |
Shiao, Stephen | IIT2016-18-SHIAO-NEOADSRS | IIT2016-18-SHIAO-NEOADSRS: Neoadjuvant radiosurgery for the treatment of metastatic brain tumors (IRB#47027) |
Siegel, Robert | CT-G20-12 | A Randomized, Double-Blind, Placebo-Controlled, Sequential, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-G20 in Subjects with Hypertrophic Obstructive Cardiomyopathy |
Vescio, Robert | ION251-CS1 | ION251-CS1: A Phase I Study of ION251 Administered by Intravenous Infusion to Patients with Relapsed/Refractory Multiple Myeloma (IRB#972) |
Wentzel, Kristopher | 9801-CL-0101 | 9801-CL-0101: A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced/Metastatic Solid Tumors (IRB#57758) |
Wentzel, Kristopher | XL092-001 | XL092-001: A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors (IRB#1111) |
Zumsteg, Zachary | NRG-GU007 | NRG-GU007: Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (IRB#184) |